The best treatment for malaria depends on which parasite species caused the infection, where it was acquired, and how severe it is. For the most dangerous and common form, caused by P. falciparum, artemisinin-based combination therapies (ACTs) are the global standard. The preferred option, when readily available, is artemether-lumefantrine, a pill taken over three days. For severe malaria of any type, intravenous artesunate is the only recommended treatment and should be started immediately.
ACTs for Uncomplicated Malaria
Most malaria cases are “uncomplicated,” meaning the infection hasn’t yet damaged organs or caused life-threatening complications. For these cases, ACTs work by combining a fast-acting artemisinin compound that rapidly kills most of the parasites in your blood with a longer-lasting partner drug that clears the rest over several days. This two-pronged approach is what makes ACTs so effective and helps slow the development of drug resistance.
Artemether-lumefantrine is the preferred first-line ACT. It’s a three-day course: you take an initial dose, a second dose eight hours later, then two doses per day on days two and three. It’s available as a fixed-dose combination tablet, and the number of tablets per dose is based on body weight. Adults weighing 35 kg (about 77 lbs) or more take four tablets per dose. Children as small as 5 kg can be treated with a single tablet per dose.
Atovaquone-proguanil is an alternative, also taken for three days but as a once-daily dose. Both options are effective against chloroquine-resistant P. falciparum, which is the dominant form in most of sub-Saharan Africa and Southeast Asia. In the few remaining areas where chloroquine still works, it can be used instead.
Treating Severe Malaria
Severe malaria is a medical emergency. It can involve seizures, organ failure, severe anemia, or dangerously high levels of parasites in the blood. Regardless of which species caused it, the treatment is intravenous artesunate. It’s the only IV antimalarial available in the United States and the global gold standard for severe cases.
The drug is given at 0, 12, and 24 hours after treatment starts. If parasite levels remain above 1% after those first three doses, treatment continues once daily for up to six additional days. Once a patient improves enough to take pills, they’re switched to a full course of an oral ACT to finish clearing the infection.
Preventing Relapse With P. vivax and P. ovale
Two malaria species, P. vivax and P. ovale, can hide dormant in the liver and cause relapses weeks or even months after the initial infection clears. Killing these dormant forms requires an additional step called “radical cure,” which the standard ACTs don’t accomplish on their own.
For radical cure, the WHO recommends a 14-day course of primaquine after the initial treatment. A newer single-dose alternative, tafenoquine, is also available. Both drugs carry an important safety concern: they can trigger a serious breakdown of red blood cells in people with G6PD deficiency, an inherited enzyme condition that’s especially common in malaria-endemic regions. Testing for G6PD deficiency before starting either drug is essential.
Treatment During Pregnancy
Malaria in pregnancy poses risks to both the mother and the developing baby, and treatment options vary by trimester. Since 2006, ACTs have been recommended for pregnant women in their second and third trimesters. The first trimester was historically treated more cautiously with a combination of quinine and clindamycin.
That guidance has shifted. Based on a 2022 evidence review, the WHO now recommends artemether-lumefantrine as the preferred treatment for uncomplicated P. falciparum malaria even in the first trimester, since it has the most human safety data of any ACT. This change reflects growing confidence in the drug’s safety profile during early pregnancy.
Common Side Effects of ACTs
Artemether-lumefantrine is generally well tolerated, but side effects can overlap with malaria symptoms themselves, making them hard to distinguish at first. The most common include headache, dizziness, fatigue, muscle or joint pain, loss of appetite, and trouble sleeping. Vomiting, fever, and chills also occur, though these are often from the malaria rather than the medication.
Rarely, the drug can cause heart rhythm changes, specifically a fast or abnormal heartbeat. Signs of a serious allergic reaction, such as swelling of the face or throat, difficulty breathing, or a rash, require emergency attention. These serious reactions are uncommon.
The Growing Threat of Drug Resistance
Artemisinin partial resistance, where the parasite takes longer to clear from the blood but can still be treated, was first identified in Southeast Asia’s Greater Mekong subregion. More concerning is that some parasites there have also developed resistance to ACT partner drugs, causing certain combinations to fail outright. Alternative ACTs still work in the region, but the options are narrowing.
Resistance has now been confirmed in parts of Africa as well, specifically in Eritrea, Rwanda, Uganda, and Tanzania. In 2022, the WHO launched a dedicated strategy to track resistance across Africa, identify the most at-risk populations, and develop alternative treatments. For now, ACTs remain effective across the continent, but this is the most closely watched problem in malaria medicine.
Malaria Vaccines as Prevention
Treatment works best when paired with prevention, and for the first time, vaccines are part of that equation. Two malaria vaccines, RTS,S and R21, are now WHO-prequalified and recommended for children living in areas where malaria is common, particularly regions with moderate to high transmission. Both target P. falciparum, the deadliest species.
The standard schedule is four doses starting at around five months of age. In areas with highly seasonal transmission or where risk stays high into a child’s third year, a fifth dose may be given. The two vaccines have not been compared head-to-head, and there is currently no evidence that one outperforms the other. Country-level decisions are based on supply, cost, and logistics.
As of now, 25 African countries are offering malaria vaccines through their childhood immunization programs, with more than 10 million children targeted annually. Five of those countries have introduced the vaccine nationally, while the rest are rolling it out in subnational phases. Vaccines don’t eliminate the need for treatment, but they significantly reduce the number of severe cases and deaths in young children, the group most vulnerable to the disease.